Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.51 |
| ▸ | LPL | P06858 | 9/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291935 | 0.88 | LIPG (0.53) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL30596099 | 0.88 | LIPG (0.53) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL24239149 | 0.87 | LIPG (0.42) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL22248793 | 0.87 | LIPG (0.55) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL27342201 | 0.86 | LIPG (0.50) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL20109573 | 0.85 | LIPG (0.57) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL22697850 | 0.84 | LIPG (0.61) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL24434088 | 0.82 | LIPG (0.46) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL23504617 | 0.82 | LIPG (0.49) | LIPGLPLALOX5MEN1CYP2C19 | |
| SCHEMBL12925749 | 0.82 | LIPG (0.46) | LIPGLPLALOX5MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180123048-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2018-05-03 | — | — | US | disclosed |
| US-20180123048-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180123048-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | PIEZO1, OCIAD1, LEF1 | LIPG 1295/4885LPL 2598/4885ALOX5 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.